{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:57:14Z","timestamp":1793383034976,"version":"4.5.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jaad.2019.06.1309","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T11:15:40Z","timestamp":1562238940000},"page":"267-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":383,"title":["Dermatomyositis: Clinical features and pathogenesis"],"prefix":"10.1016","volume":"82","author":[{"given":"Madeline E.","family":"DeWane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2019.06.1309_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2474-13-103","article-title":"Incidence and\u00a0prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis","volume":"13","author":"Smoyer-Tomic","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jaad.2019.06.1309_bib2","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/ard.2008.093161","article-title":"Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences","volume":"68","author":"Bernatsky","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2019.06.1309_bib3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/mus.23302","article-title":"Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan","volume":"45","author":"Furst","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaad.2019.06.1309_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2019.06.1309_bib5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mus.24566","article-title":"An overview of polymyositis and dermatomyositis","volume":"51","author":"Findlay","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaad.2019.06.1309_bib6","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3389\/fimmu.2017.00992","article-title":"Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer","volume":"8","author":"Aussy","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archdermatol.2009.328","article-title":"Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota","volume":"146","author":"Bendewald","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.11122","article-title":"US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry","volume":"49","author":"Mendez","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-016-0134-0","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease","volume":"15","author":"Kim","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jaad.2019.06.1309_bib10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2133.2007.08055.x","article-title":"A systematic review of juvenile-onset clinically amyopathic dermatomyositis","volume":"157","author":"Gerami","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2017.12.055","article-title":"Applicability of EULAR\/ACR classification criteria for dermatomyositis to amyopathic disease","volume":"79","author":"Patel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12016-017-8652-1","article-title":"Cutaneous manifestations of dermatomyositis: a comprehensive review","volume":"53","author":"Mainetti","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.clindermatol.2018.04.003","article-title":"Dermatomyositis: current concepts","volume":"36","author":"Bogdanov","year":"2018","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib14","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.06.1309_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2004.12.015","article-title":"Cutaneous symptoms of dermatomyositis significantly impact patients\u2019 quality of life","volume":"54","author":"Hundley","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","article-title":"Quality of life in dermatomyositis","volume":"65","author":"Goreshi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180308","article-title":"Current classification and management of inflammatory myopathies","volume":"5","author":"Schmidt","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.jaad.2019.06.1309_bib18","first-page":"165","article-title":"Prognosis of dysphagia in dermatomyositis","volume":"37","author":"Ogawa-Momohara","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib20","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2019.06.1309_bib21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.nmd.2014.12.001","article-title":"205th ENMC International Workshop: pathology diagnosis of idiopathic inflammatory myopathies part II 28\u201330 March 2014, Naarden, The Netherlands","volume":"25","author":"De Bleecker","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jaad.2019.06.1309_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaut.2013.11.005","article-title":"The clinical features, diagnosis and classification of dermatomyositis","volume":"48-49","author":"Iaccarino","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaad.2019.06.1309_bib23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1212\/WNL.0000000000003568","article-title":"Sarcoplasmic MxA expression: a valuable marker of dermatomyositis","volume":"88","author":"Uruha","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2019.06.1309_bib24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.autrev.2017.05.003","article-title":"Integrated Diagnosis Project for Inflammatory Myopathies: an association between autoantibodies and muscle pathology","volume":"16","author":"Suzuki","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"pt 7","key":"10.1016\/j.jaad.2019.06.1309_bib25","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/brain\/aww122","article-title":"Microvascular alterations and the role of complement in dermatomyositis","volume":"139","author":"Lahoria","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.jaad.2019.06.1309_bib26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jaad.2019.06.1309_bib27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","article-title":"Acquired immune and inflammatory myopathies: pathologic classification","volume":"23","author":"Pestronk","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib28","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/art.38137","article-title":"Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders","volume":"65","author":"Miller","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib29","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","article-title":"Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups","volume":"75","author":"Rothwell","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2019.06.1309_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.md.0000217525.82287.eb","article-title":"Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies","volume":"85","author":"O\u2019Hanlon","year":"2006","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib31","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3899\/jrheum.170165","article-title":"HLA-DRB1 Alleles as genetic risk factors for the development of anti-MDA5 antibodies in patients with dermatomyositis","volume":"44","author":"Chen","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.berh.2009.07.007","article-title":"Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment","volume":"23","author":"Wedderburn","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes","volume":"280","author":"Rider","year":"2016","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaad.2019.06.1309_bib34","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.autrev.2017.07.021","article-title":"Using multi-omics methods to understand dermatomyositis\/polymyositis","volume":"16","author":"Gao","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2019.06.1309_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2217\/epi-2018-0064","article-title":"Integrated comparison of the miRNAome and mRNAome in muscles of dermatomyositis and polymyositis reveals common and specific miRNA-mRNAs","volume":"11","author":"Gao","year":"2019","journal-title":"Epigenomics"},{"key":"10.1016\/j.jaad.2019.06.1309_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-4419-8216-2_6","article-title":"Environmental agents and autoimmune diseases","volume":"711","author":"Miller","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib37","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.24702","article-title":"Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women","volume":"60","author":"Love","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib38","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/art.37985","article-title":"Childhood Myositis Heterogeneity Collaborative Study Group. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis","volume":"65","author":"Shah","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib39","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1568-9972(02)00055-1","article-title":"The pathogenesis of inflammatory muscle diseases: on the cutting edge among the environment, the genetic background, the immune response and the dysregulation of apoptosis","volume":"1","author":"Pignone","year":"2002","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2019.06.1309_bib40","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/rheumatology\/kex162","article-title":"Environmental factors associated with disease flare in juvenile and adult dermatomyositis","volume":"56","author":"Mamyrova","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib41","first-page":"7384681","article-title":"Clinically amyopathic dermatomyositis caused by a tattoo","volume":"2018","author":"Han","year":"2018","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jaad.2018.08.019","article-title":"Acute onset\/flares of dermatomyositis following ingestion of IsaLean herbal supplement: clinical and immunostimulatory findings","volume":"80","author":"Zeidi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib43","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ana.410270402","article-title":"Microvascular changes in early and advanced dermatomyositis: a quantitative study","volume":"27","author":"Emslie-Smith","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib44","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrrheum.2010.2","article-title":"Immunotherapy of myositis: issues, concerns and future prospects","volume":"6","author":"Dalakas","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib45","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.nmd.2018.09.002","article-title":"Pattern of myogenesis and vascular repair in early and advanced lesions of juvenile dermatomyositis","volume":"28","author":"Baumann","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jaad.2019.06.1309_bib46","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun"},{"key":"10.1016\/j.jaad.2019.06.1309_bib48","article-title":"Discovery of key genes in dermatomyositis based on the gene expression omnibus database","author":"Xie","year":"2019","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib49","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/rheumatology\/kex468","article-title":"Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics","volume":"57","author":"Karasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12016-015-8513-8","article-title":"The clinical features of myositis-associated autoantibodies: a review","volume":"52","author":"Gunawardena","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib53","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib54","doi-asserted-by":"crossref","first-page":"e000507","DOI":"10.1136\/rmdopen-2017-000507","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report","volume":"3","author":"Bottai","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.jaad.2019.06.1309_bib55","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib56","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/jdv.14759","article-title":"Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients","volume":"32","author":"Best","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib57","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","article-title":"Recent advances in dermatomyositis-specific autoantibodies","volume":"28","author":"Fujimoto","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","article-title":"Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies","volume":"20","author":"Wolstencroft","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jaad.2019.06.1309_bib59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaad.2019.06.1309_bib60","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4081\/cp.2017.922","article-title":"investigating idiopathic inflammatory myopathy; initial cross specialty experience with use of the extended myositis antibody panel","volume":"7","author":"O\u2019Connor","year":"2017","journal-title":"Clin Pract"},{"key":"10.1016\/j.jaad.2019.06.1309_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.18133","article-title":"Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice","author":"Gandiga","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11926-013-0335-1","article-title":"Autoantibodies in polymyositis and dermatomyositis","volume":"15","author":"Ghirardello","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jaad.2019.06.1309_bib63","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1471-2474-11-223","article-title":"Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis","volume":"11","author":"Kang","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jaad.2019.06.1309_bib64","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1346-8138.2011.01262.x","article-title":"Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients","volume":"38","author":"Ikeda","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib65","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib66","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/ar4207","article-title":"Implications in the difference of anti-Mi-2 and -p155\/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara","volume":"15","author":"Petri","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2019.06.1309_bib67","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/art.1780280711","article-title":"The association between Mi-2 antibodies and dermatomyositis","volume":"28","author":"Targoff","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib68","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/art.10358","article-title":"Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis","volume":"46","author":"Shamim","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib69","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12016-015-8496-5","article-title":"Cutaneous manifestations in dermatomyositis: key clinical and serological features-a comprehensive review","volume":"51","author":"Muro","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib70","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/bjd.15020","article-title":"Cutaneous features of dermatomyositis associated with myositis-specific antibodies","volume":"176","author":"Daly","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib71","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.berh.2017.12.003","article-title":"Juvenile dermatomyositis: latest advances","volume":"31","author":"Wu","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib72","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib73","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.39753","article-title":"Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis","volume":"68","author":"Deakin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib74","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/1756-185X.13424","article-title":"Anti-TIF1\u03b3 antibody and the expression of TIF1\u03b3 in idiopathic inflammatory myopathies","volume":"22","author":"Kim","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaad.2019.06.1309_bib75","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/art.33402","article-title":"TIF1 autoantibodies in dermatomyositis shed insight into the cancer-myositis connection","volume":"64","author":"Fiorentino","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib76","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib77","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib78","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib79","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","article-title":"Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy","volume":"201","author":"Casciola-Rosen","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2019.06.1309_bib80","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamadermatol.2016.1429","article-title":"Ovoid palatal patch in dermatomyositis: a novel finding associated with anti-TIF1\u03b3 (p155) antibodies","volume":"152","author":"Bernet","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib81","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib82","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mus.25507","article-title":"High-resolution manometry in patients with idiopathic inflammatory myopathy: elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset","volume":"56","author":"Casal-Dominguez","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaad.2019.06.1309_bib83","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib84","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib86","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10067-015-2935-9","article-title":"Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis\/dermatomyositis","volume":"34","author":"Chen","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib87","first-page":"891","article-title":"Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis","volume":"32","author":"Ceribelli","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib88","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/tan.13171","article-title":"Genetic association of HLA-DRB1 multiple polymorphisms with dermatomyositis in Chinese population","volume":"90","author":"Lin","year":"2017","journal-title":"HLA"},{"key":"10.1016\/j.jaad.2019.06.1309_bib89","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/03009742.2017.1340512","article-title":"Anti-MDA5-positive dermatomyositis: an emerging entity with a variable clinical presentation","volume":"46","author":"Ortiz-Santamaria","year":"2017","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib90","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","article-title":"Management of myositis-related interstitial lung disease","volume":"150","author":"Morisset","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2019.06.1309_bib91","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib92","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/rheumatology\/key386","article-title":"The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients","volume":"58","author":"Ono","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib93","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Anti-melanoma differentiation\u2013associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib94","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of\u00a0dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib95","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.jaad.2019.06.1309_bib96","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2019.06.1309_bib97","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","article-title":"Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis","volume":"158","author":"Kobayashi","year":"2011","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2019.06.1309_bib98","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jaad.2019.06.1309_bib99","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.23210","article-title":"Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients","volume":"69","author":"Rogers","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib100","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/rheumatology\/kes033","article-title":"Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2","volume":"51","author":"Ishikawa","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib101","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.jaad.2019.06.1309_bib102","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/art.24547","article-title":"Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis","volume":"60","author":"Gunawardena","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib103","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ard.2008.097162","article-title":"Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis","volume":"68","author":"Betteridge","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2019.06.1309_bib104","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00403-016-1704-1","article-title":"Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets","volume":"309","author":"Merlo","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2019.06.1309_bib105","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamadermatol.2018.2549","article-title":"Association between autoantibody phenotype and cutaneous adverse reactions to hydroxychloroquine in dermatomyositis","volume":"154","author":"Wolstencroft","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib106","first-page":"505","article-title":"Cutaneous signs of classical dermatomyositis","volume":"149","author":"Auriemma","year":"2014","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib107","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/acr.23338","article-title":"Assessment of microvascular abnormalities by nailfold capillaroscopy in juvenile dermatomyositis after medium- to long-term followup","volume":"70","author":"Barth","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib108","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.semarthrit.2017.06.001","article-title":"State of the art on nailfold capillaroscopy in dermatomyositis and polymyositis","volume":"47","author":"Bertolazzi","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib109","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10067-014-2795-8","article-title":"Nailfold capillaroscopic changes in dermatomyositis and polymyositis","volume":"34","author":"Manfredi","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib110","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.1994.03520240067043","article-title":"Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed","volume":"272","author":"Kasteler","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2019.06.1309_bib111","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.annder.2018.11.010","article-title":"Mechanics hands in patients with antisynthetase syndrome: 25 cases","volume":"146","author":"Gusdorf","year":"2019","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib112","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/ced.12948","article-title":"Physician, beware! The deckchair sign can be seen in dermatomyositis","volume":"41","author":"Wernham","year":"2016","journal-title":"Clin Exp Dermatol"},{"issue":"5 pt 2","key":"10.1016\/j.jaad.2019.06.1309_bib113","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1067\/mjd.2000.102648","article-title":"An unusual presentation of dermatomyositis: the type Wong variant revisited","volume":"43","author":"Lupton","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib114","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0140-6736(00)05118-7","article-title":"Raynaud\u2019s phenomenon","volume":"357","author":"Block","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2019.06.1309_bib115","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/ppul.22742","article-title":"The lung is involved in juvenile dermatomyositis","volume":"48","author":"Pouessel","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib116","doi-asserted-by":"crossref","first-page":"e000291","DOI":"10.1136\/rmdopen-2016-000291","article-title":"Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies","volume":"2","author":"Schwartz","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.jaad.2019.06.1309_bib117","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/CRD.0000000000000241","article-title":"Cardiac manifestations in idiopathic inflammatory myopathies: an overview","volume":"27","author":"Jayakumar","year":"2019","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.jaad.2019.06.1309_bib118","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1136\/annrheumdis-2013-203279","article-title":"In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity","volume":"73","author":"Schwartz","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2019.06.1309_bib119","first-page":"535","article-title":"In juvenile dermatomyositis, heart rate variability is reduced, and associated with both cardiac dysfunction and markers of inflammation: a cross-sectional study median 13.5 years after symptom onset","volume":"55","author":"Barth","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.rdc.2017.09.006","article-title":"Gastrointestinal and hepatic disease in the inflammatory myopathies","volume":"44","author":"Gadiparthi","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2019.06.1309_bib121","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-213460","article-title":"Colonic vasculopathy and perforation in the initial presentation of adult dermatomyositis in a patient with improving muscle weakness","volume":"2016","author":"Kibbi","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2019.06.1309_bib122","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fped.2018.00284","article-title":"The vasculopathy of juvenile dermatomyositis","volume":"6","author":"Papadopoulou","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaad.2019.06.1309_bib123","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2019.06.1309_bib124","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/rheumatology\/kel099","article-title":"The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)\u2013clinical characteristics of children recruited within the first 5 yr","volume":"45","author":"McCann","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib125","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/rheumatology\/kep302","article-title":"Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset","volume":"48","author":"Sanner","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2019.06.1309_bib126","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/art.22782","article-title":"Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy","volume":"57","author":"Mamyrova","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib127","article-title":"Asymptomatic multifocal paracentral acute middle maculopathy associated with juvenile dermatomyositis: optical coherence angiography findings","author":"Starr","year":"2019","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.jaad.2019.06.1309_bib128","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/art.24411","article-title":"Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis","volume":"60","author":"L\u00f3pez De Padilla","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2019.06.1309_bib129","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/art.22993","article-title":"Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients","volume":"57","author":"Miles","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"pt 8","key":"10.1016\/j.jaad.2019.06.1309_bib130","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.jaad.2019.06.1309_bib131","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/BOR.0000000000000438","article-title":"Immune-mediated necrotizing myopathy associated with statins: history and recent developments","volume":"29","author":"Tiniakou","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2019.06.1309_bib132","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.24919","article-title":"Pathomechanisms of anti-cytosolic 5\u2019-nucleotidase 1A autoantibodies in sporadic inclusion body myositis","volume":"81","author":"Tawara","year":"2017","journal-title":"Ann Neurol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219323096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219323096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:51:59Z","timestamp":1759272719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219323096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":132,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0190962219323096"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1309","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatomyositis: Clinical features and pathogenesis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(19)33265-7","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}